Forget Moderna: This Biotech Juggernaut Is Rising Fast
A biotech powerhouse is drawing fresh attention as Moderna slows, delivering stronger cash flow, patent extensions, a...
Fund reallocation matters when priorities shift. This intro explains why adjusting allocations supports your financial plan.
21,833 articlesA biotech powerhouse is drawing fresh attention as Moderna slows, delivering stronger cash flow, patent extensions, a...
The S&P 500 dividend yield fell to a historic low in 2026, forcing a rethink of retirement income. This piece explain...
A famed Bronx Zoo elephant dies at 55, highlighting how aging animals, care costs, and donor funding shape the financ...
Primerica's earnings trajectory hinges on policy sales, investment product performance, and agent distribution. This ...
A 62-year-old retiree faces the challenge of sustaining $65,000 in annual spending with investment income. This piece...
The ProShares Ultra Technology ETF fell sharply on Friday as NVIDIA and Broadcom headlines collided with tech stocks,...
This week’s CPI data could tilt policy expectations: a hotter print may bolster a hawkish stance from the new Fed lea...
Turning 60 is a turning point, not a deadline. This guide shares best retirement strategies for your 60s, including S...
As GBTC’s 1.50% fee persists, the cost compounds for long-horizon investors. This piece compares the drag to cheaper ...
BlackRock indicates bitcoin’s portfolio role is evolving toward a small, strategic allocation as more institutions se...
The BIS warns that stablecoins becoming central bank policy questions are moving from crypto markets into sovereign d...
As the 2026 COLA lands at 2.8%, retirees face a growing gap between checks and living costs. A disciplined four-ETF i...